Sahajanand Medical Technologies Sets Q2 FY27 Results Meeting

Sahajanand Medical Technologies Limited has scheduled its board meeting for November 5, 2026, to consider unaudited standalone and consolidated results for Q2 FY27 and the half year ended September 30, 2026, following FY26 operating revenue growth of 18% to ₹1,214 crore. The disclosure sets the date for the company’s next formal financial update.

When will Sahajanand Medical Technologies announce Q2 FY27 results?

Sahajanand Medical Technologies Limited will consider and approve its Q2 FY27 financial results at a board meeting on November 5, 2026. The agenda covers unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Q2 FY27 covers the July-September 2026 period.

The company has also scheduled an earnings conference call on the same day from 6:30 p.m. to 7:30 p.m. IST. Motilal Oswal Financial Services Limited will host the call, with the Managing Director and Chief Executive Officer and the Chief Financial Officer expected to participate. The session is intended to discuss Q2 and H1 FY27 financial results after the announcement.

What financial figures has SMT reported so far?

SMT’s reported Q1 FY26-27 revenue stood at ₹351.67 crore, while operating profit was ₹48.58 crore. Profit before depreciation and tax was ₹44.70 crore, profit before tax was ₹24.29 crore, and net profit was ₹15.09 crore, according to the supplied quarterly-results summary.

The same summary displays zero per cent quarter-on-quarter and year-on-year changes for these Q1 figures, but does not provide the comparative revenue or profit amounts. Therefore, those displayed percentage changes do not provide a basis for assessing the underlying trend beyond the reported absolute numbers.

How did SMT perform in FY26?

SMT’s FY26 operating revenue rose 18% to ₹1,214 crore from ₹1,032 crore in FY25. Operating margin remained broadly stable at 13.14% in FY26, compared with 12.87% in FY25. These figures provide the most recent full-year operating context ahead of the Q2 FY27 release.

A separate set of reported annual figures showed revenue of ₹551.20 crore in 2026 versus ₹530.29 crore in 2025. Net profit was ₹43.50 crore in 2026, compared with a loss of ₹7.92 crore in 2025. Earnings per share was ₹4.45 in 2026, while book value per share was ₹69.02. The supplied information does not specify whether these annual figures use the same reporting basis as the operating-revenue data.

What does the November 5 update mean for investors?

The November 5 disclosure is a scheduled corporate action rather than an announcement of Q2 FY27 financial performance. Investors will receive the unaudited standalone and consolidated numbers for the September quarter and the first half of FY27 when the board considers the results.

The earnings call may provide management commentary on the reported numbers and business operations. However, no Q2 revenue, margin, profit, guidance, order details, or capital-allocation decision has been disclosed in the provided material. Any assessment of the quarter’s effect on valuation or future earnings would therefore require the financial release and management discussion.

What business does Sahajanand Medical Technologies operate?

SMT manufactures and distributes Class III and Class C/D medical devices. Its stated markets include India, Europe, the rest of Asia Pacific, Latin America, and the Middle East and Africa. The company’s results are therefore relevant to investors tracking medical-device manufacturing and international distribution operations.

The company’s disclosed FY26 margin of 13.14%, against 12.87% in FY25, indicates that profitability at the operating level was maintained alongside revenue growth during that year. The forthcoming results will add current-period data for a business that operates across multiple geographies, but the supplied information does not disclose a regional revenue split or product-level performance.

Conclusion

The key confirmed development is that SMT’s board will meet on November 5, 2026, to consider unaudited Q2 FY27 and H1 FY27 results. The company enters that update after reporting FY26 operating revenue of ₹1,214 crore, up 18% year on year, with operating margin at 13.14%.

Investors should watch the financial results announcement and the 6:30 p.m. IST earnings call on November 5 for reported Q2 and H1 figures, management commentary, and any disclosures on operations. The current material does not provide Q2 estimates or a financial outlook beyond the scheduled reporting event.